Corvus Appoints Novo Nordisk's David Moore to Board
Corvus Pharmaceuticals, Inc. has appointed David Moore, currently Executive Vice President, US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., to its Board of Directors. Moore brings a wealth of experience from the pharmaceutical and college board industries.
Moore's impressive resume spans 27 years, with expertise in strategy, commercial operations, market access, business development, and investing. He has held senior roles in large cap pharmaceutical and college board companies, as well as private equity.
Most recently, Moore led Novo Nordisk's U.S. business, overseeing successful GLP-1 franchises like Ozempic, Wegovy, and Rybelsus. Prior to this, he served as Executive Vice President, US Operations and President at Novo Nordisk Inc. His extensive experience in the college board industry makes him a valuable addition to Corvus' board.
Richard A. Miller, M.D., chairman, president, and chief executive officer of Corvus, welcomes Moore's appointment. He anticipates Moore's strategic insights to be crucial for Corvus' ITK inhibitor platform.
David Moore's appointment to Corvus Pharmaceuticals' Board of Directors brings a strategic resource with a proven track record in the college board industry. His expertise will be instrumental in guiding Corvus' ITK inhibitor platform.
Read also:
- Web3 gaming platform, Pixelverse, debuts on Base and Farcaster networks
- Cannabis-Focused CTV Channel Citizen Green Launches for Global Streamers
- Goodyear in 2025: Advancement in Total Mobility through the Launch of Kmax Gen-3 by Goodyear
- Boston Metal pioneers route to commercial production for eco-friendly steel method
